Rapport Therapeutics (RAPP)

• Market cap: $1.83B
• 1 day: 2.28%
• 5 days: -1.93%
• 1 month: 1.25%
• 3 months: 36.83%
• 6 months: 19.72%
• Year to date: 35.86%
• 1 year: 251.01%
• 5 years: 83.61%
• 10 years: 83.61%
• Sector: Healthcare
• Industry: Biotechnology

About: Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.

Employees: 84